Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Core Viewpoint - Yifeng Pharmacy (603939) announced an increase in guarantees for its subsidiary Shijiazhuang Xinxing by 585 million yuan, raising the total guarantee balance to 950 million yuan, with no overdue guarantees reported [1] Summary by Relevant Categories Company Guarantees - The company has provided additional guarantees amounting to 585 million yuan for its subsidiary, bringing the cumulative guarantee balance to 950 million yuan [1] - The total external guarantees provided by the company and its subsidiaries amount to 2.56 billion yuan, which represents 23.87% of the most recent audited net assets [1]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象 被担保人名称 石家庄新兴药房连锁有限公司（以下简 称"石家庄新兴"） 本次担保金额 58,500.00 万元 实际为其提供的担保余额 95,000.00 万元 是否在前期预计额度内 ☑是 □否 □不适用：_________ 本次担保是否有反担保 □是 ☑否 □不适用：_________ （二）内部决策程序 公司于 2025 年 4 月 28 日召开的第五届董事会第十六次会议与 2025 年 5 月 29 日召开的 2024 年年度股东会，审议通过了《关于为子公司申请银行授信提供 担保的议案》，石家庄新兴因经营发展需要，向银行申请授信额度，公司对其授 信进行担保，担保总额合计不超过 194,500.00 万元 ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

Market Performance - The pharmaceutical commercial sector increased by 1.77% compared to the previous trading day, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Individual Stock Performance - Jia Shitang (002462) closed at 15.80, up 10.03% with a trading volume of 224,800 shares [1] - Saily Medical (603716) closed at 22.61, up 10.02% with a trading volume of 133,500 shares [1] - Baiyang Pharmaceutical (301015) closed at 25.23, up 6.91% with a trading volume of 83,200 shares [1] - Other notable performers include Dajia Weikang (301126) up 6.51%, and Run Da Medical (603108) up 5.82% [1] Capital Flow Analysis - The pharmaceutical commercial sector saw a net inflow of 231 million yuan from institutional investors, while retail investors contributed a net inflow of 71.88 million yuan [2] - However, there was a net outflow of 303 million yuan from speculative funds [2] Detailed Capital Flow for Key Stocks - Saily Medical (603716) had a net inflow of 1.59 billion yuan from institutional investors, but a net outflow of 71.84 million yuan from speculative funds [3] - Jia Shitang (002462) experienced a net inflow of 86.98 million yuan from institutional investors, with a net outflow of 45.96 million yuan from speculative funds [3] - Hua Ren Health (301408) had a net inflow of 45.75 million yuan from institutional investors, but a significant net outflow of 65.32 million yuan from retail investors [3]

未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"益丰转债"面值 为人民币 1,797,249,000 元，占"益丰转债"发行总量的比例为 99.9898%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有面值 183,000 元"益丰转 债"转为公司 A 股普通股，累计转股股数为 5,571 股，占"益丰转债"转股前 公司已发行普通股股份总额的 0.0005%。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于可转债转股结果暨股份变动公告 的"益丰转债"自2024年9月9日起可转换为公司股份。 本季度转股情况："益丰转债"自 2024 年 9 月 9 日起可转换为公司股份，2025 年 10 月 1 日至 2025 年 12 月 31 日共有面值 2, ...

Core Viewpoint - Yifeng Pharmacy has indicated that due to multiple factors such as the economic environment and industry cycles, the company will focus on improving operational quality, leading to a reduction in store openings and acquisition plans, resulting in a slowdown in revenue growth compared to previous periods [1] Group 1: Company Performance - For the period from January to September 2025, Yifeng Pharmacy achieved revenue of 17.286 billion yuan, representing a year-on-year growth of 0.39% [1] - The company reported a net profit attributable to shareholders of 1.225 billion yuan, which is a year-on-year increase of 10.27% [1] Group 2: Industry Outlook - The fundamental development logic of the industry remains unchanged, driven by factors such as accelerated population aging, medical reform separating medicine from medical services, and increased industry concentration [1] - Retail pharmacies are expected to continue to enhance their channel and social value as important entry points for community health [1] - The retail pharmacy industry is anticipated to experience new development opportunities with the ongoing innovation in diversified operations and the maturation of new retail models both online and offline [1]

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Market Overview - The pharmaceutical commercial sector declined by 0.69% on December 31, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 23.60, up 2.61% with a trading volume of 41,600 shares and a transaction value of 97.15 million [1] - Nanjing Pharmaceutical (600713) closed at 5.46, up 1.49% with a trading volume of 197,800 shares and a transaction value of 107 million [1] - Run Da Medical (603108) closed at 14.95, up 0.88% with a trading volume of 103,700 shares and a transaction value of 155 million [1] - Other notable stocks include Liuyuan Group (603368) at 17.82, up 0.62%, and China Pharmaceutical (600056) at 10.33, up 0.29% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 781 million from institutional investors, while retail investors saw a net inflow of 762 million [2] - The main capital inflow and outflow for selected stocks include: - Huaren Health (301408) with a net inflow of 83.36 million from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 22.40 million from institutional investors [3] - Yifeng Pharmacy (603939) with a net inflow of 19.37 million from institutional investors [3]